Abstract:Microneedle patches coated with solid-state influenza vaccine have been developed to improve vaccine efficacy and patient coverage. However, dip coating microneedles with influenza vaccine can reduce antigen activity. In this study, we sought to determine the experimental factors and mechanistic pathways by which inactivated influenza vaccine can lose activity, as well as develop and assess improved microneedle coating formulations that protect the antigen from activity loss. After coating microneedles using a standard vaccine formulation, the stability of influenza vaccine was reduced to just 2%, as measured by hemagglutination activity. The presence of carboxymethylcellulose, which was added to increase viscosity of the coating formulation, was shown to contribute to vaccine activity loss. After screening a panel of candidate stabilizers, the addition of trehalose to the coating formulation was found to protect the antigen and retain 48–82% antigen activity for all three major strains of seasonal influenza: H1N1, H3N2 and B. Influenza vaccine coated in this way also exhibited thermal stability, such that activity loss was independent of temperature over the range of 4–37°C for 24h. Dynamic light scattering measurements showed that antigen activity loss was associated with virus particle aggregation, and that stabilization using trehalose largely blocked this aggregation. Finally, microneedles using an optimized vaccine coating formulation were applied to the skin to vaccinate mice. Microneedle vaccination induced robust systemic and functional antibodies and provided complete protection against lethal challenge infection similar to conventional intramuscular injection. Overall, these results show that antigen activity loss during microneedle coating can be largely prevented through optimized formulation and that stabilized microneedle patches can be used for effective vaccination.

Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin.

Enhanced Memory Responses to Seasonal H1n1 Influenza Vaccination of the Skin with the Use of Vaccine-Coated Microneedles

Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity

Improved Influenza Vaccination in the Skin Using Vaccine Coated Microneedles

Influenza Immunization with Trehalose-Stabilized Virus-Like Particle Vaccine Using Microneedles.

Stability of Influenza Vaccine Coated Onto Microneedles.

Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine

Long-Term Protective Immunity from an Influenza Virus-Like Particle Vaccine Administered with a Microneedle Patch

Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles

Microneedle Delivery of Trivalent Influenza Vaccine to the Skin Induces Long-Term Cross-Protection

Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination

Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch

Intradermal Administration of Influenza Vaccine with Trehalose and Pullulan-Based Dissolving Microneedle Arrays.

Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage

Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch

Microneedle Delivery of H5n1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice

Coated Porous Microneedles for Effective Intradermal Immunization with Split Influenza Vaccine

Local Response to Microneedle-Based Influenza Immunization in the Skin

Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection

Microneedle Delivery of an M2e-TLR5 Ligand Fusion Protein to Skin Confers Broadly Cross-Protective Influenza Immunity.